Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Avalo Therapeutics (AVTX) over the last 8 years, with Q3 2025 value amounting to $421397.0.

  • Avalo Therapeutics' Treasury Shares fell 3333.38% to $421397.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $421397.0, marking a year-over-year decrease of 3333.38%. This contributed to the annual value of $632100.0 for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Avalo Therapeutics' Treasury Shares is $421397.0, which was down 3333.38% from $421397.0 recorded in Q2 2025.
  • Avalo Therapeutics' 5-year Treasury Shares high stood at $632100.0 for Q3 2024, and its period low was $11250.0 during Q4 2021.
  • Moreover, its 4-year median value for Treasury Shares was $288615.0 (2021), whereas its average is $286255.6.
  • In the last 5 years, Avalo Therapeutics' Treasury Shares crashed by 9278.07% in 2021 and then tumbled by 3333.38% in 2025.
  • Over the past 4 years, Avalo Therapeutics' Treasury Shares (Quarter) stood at $11250.0 in 2021, then changed by 0.0% to $11250.0 in 2022, then soared by 5518.67% to $632100.0 in 2024, then plummeted by 33.33% to $421397.0 in 2025.
  • Its Treasury Shares was $421397.0 in Q3 2025, compared to $421397.0 in Q2 2025 and $421397.0 in Q1 2025.